secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001193125-26-120691
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx updates corporate presentation: Phase 3 LUCIDITY enrollment complete, Phase 2 PREVENT analysis added
--------------------------------------------------------------------------------

- Completed enrollment in Phase 3 LUCIDITY trial.
- Added exploratory analysis of Phase 2 PREVENT study from ENDO 2025.
- Completed enrollment for Cohort 2 of Phase 1 LUMINA trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526120691/0001193125-26-120691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526120691/d49067d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-120691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer